News from rigel pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-NMS:RIGL)

Jan 28, 2016, 07:30 ET
Rigel Pharmaceuticals, Inc.

Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)

 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that the first of two Phase 3 clinical studies of fostamatinib in immune...

Jan 07, 2016, 07:30 ET
Rigel Pharmaceuticals, Inc.

Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will...

Nov 03, 2015, 16:05 ET
Rigel Pharmaceuticals, Inc.

Rigel Announces Third Quarter 2015 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30,...

Oct 27, 2015, 07:30 ET
Rigel Pharmaceuticals, Inc.

Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2015 financial results after market...

Sep 09, 2015, 08:30 ET
Rigel Pharmaceuticals, Inc.

Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Aclaris Therapeutics International Limited (ATIL), a wholly owned subsidiary of...

Sep 08, 2015, 07:30 ET
Rigel Pharmaceuticals, Inc.

Rigel Granted Orphan Drug Designation for Fostamatinib in ITP

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to...

Aug 04, 2015, 16:05 ET
Rigel Pharmaceuticals, Inc.

Rigel Announces Second Quarter 2015 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30,...

Jul 28, 2015, 07:30 ET
Rigel Pharmaceuticals, Inc.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2015 financial results after market...

Jun 30, 2015, 07:30 ET
Rigel Pharmaceuticals, Inc.

Rigel Welcomes Keith A. Katkin to Board of Directors

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Keith A. Katkin, president and chief executive officer of Avanir...

May 28, 2015, 07:30 ET
Rigel Pharmaceuticals, Inc.

Rigel to Present at Jefferies 2015 Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled...

May 07, 2015, 16:05 ET
Rigel Pharmaceuticals, Inc.

Rigel Announces First Quarter 2015 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2015. For the first...

Apr 30, 2015, 07:30 ET

Rigel Announces Conference Call and Webcast to Report First Quarter 2015 Financial Results and Pipeline Update

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2015 financial results after market...

Mar 03, 2015, 07:30 ET
Rigel Pharmaceuticals, Inc.

Rigel Announces Fourth Quarter and Year End 2014 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended...

Feb 23, 2015, 08:03 ET
Rigel Pharmaceuticals, Inc.

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered into a...

Jan 08, 2015, 07:30 ET

Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will...

Nov 24, 2014, 07:30 ET

Rigel Announces Executive Management Changes

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as...

Nov 04, 2014, 07:30 ET

Rigel Announces Third Quarter 2014 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30,...

Aug 13, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary...

Aug 05, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Second Quarter 2014 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the...

Jul 16, 2014, 08:35 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Initiates Phase 3 Studies of Fostamatinib in ITP

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib,...